Shares of InterMune (ITMN -5.7%) tumble despite strong Q1 earnings and sales after the biotech...
Shares of InterMune (ITMN -5.7%) tumble despite strong Q1 earnings and sales after the biotech company says it isn’t in talks on a sale. Bloomberg reported yesterday that the company with an approved drug for a rare lung disease was working with Goldman Sachs to find a buyer.
From other sites
at CNBC.com (Sep 15, 2014)
at CNBC.com (Sep 11, 2014)
at MarketWatch.com (Sep 11, 2014)
at CNBC.com (Aug 28, 2014)
at CNBC.com (Aug 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs